The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Fintel reports that on December 16, 2024, JP Morgan downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Neutral ...

On Friday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.44 which represents a decrease of $-0.45 or -23.81% from the prior close of $1.89. The stock opened at $1.75 and touched ...

Editas Medicine Inc.股价跌至52周新低，触及1.89美元，较52周高点11.58美元下跌84%，该公司正面临市场挑战和投资者担忧。根据 InvestingPro 数据，尽管公司财务健康状况评分较弱，但基于公允价值分析，该股票似乎被低估。这一最新价格标志着这家生物科技公司的重大下滑，过去一年其股价已惊人地下跌了80%。这种急剧下跌反映了投资者对基因编辑板块的普遍怀疑态度，Edit ...

Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies ...

马萨诸塞州剑桥 - 目前市值约1.57亿美元的基因编辑公司Editas Medicine, Inc. (NASDAQ:EDIT)宣布战略转型,优先发展其体内CRISPR基因编辑项目,此举源于近期临床前研究的成功。该公司计划将现金储备延长至2027年第二季度,并计划在约两年内实现体内治疗的人体概念验证。根据 InvestingPro ...

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective trimmed by Evercore ISI from $7.00 to $5.00 in a report ...

Truist Financial downgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a buy rating to a hold rating in a ...